All Trials

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, metastatic squamous non-small cell lung cancer (ECOG 0-1) who receive induction with pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel, then are randomized at maintenance to pembrolizumab alone or in combination with sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate linked to a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06422143

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with untreated, stage IV squamous NSCLC whose tumors have PD-L1 expression ≥1%, randomizing them to receive first-line platinum-based chemotherapy combined with either rilvegostomig—a bispecific antibody targeting PD-1 and TIGIT—or pembrolizumab, each followed by their respective monotherapy as maintenance. Key exclusions are prior immunotherapy, active CNS disease, and significant autoimmune or infectious disorders.

ClinicalTrials.gov ID: NCT06692738

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls HLA-A2 positive patients with metastatic squamous or non-squamous NSCLC who have developed secondary resistance to immune checkpoint inhibitors and are ineligible for targeted therapies, randomizing them to receive either OSE2101, a neoepitope-based cancer vaccine designed to stimulate tumor-specific cytotoxic T-cell responses, or standard docetaxel chemotherapy.

ClinicalTrials.gov ID: NCT06472245

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC without actionable mutations who have progressed after first-line platinum-doublet chemotherapy plus immune checkpoint inhibitor; patients are randomized to either intravenous olvimulogene nanivacirepvec (an oncolytic vaccinia virus immunotherapy) followed by platinum-doublet chemotherapy and an immune checkpoint inhibitor, or to docetaxel. Patients in the docetaxel arm may cross over to the investigational regimen upon progression.

ClinicalTrials.gov ID: NCT06463665

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously treated, advanced or metastatic NSCLC harboring homozygous MTAP deletion (and no actionable driver mutations), evaluating the oral PRMT5 inhibitor AMG 193, which targets MTAP-deleted tumors via synthetic lethality. AMG 193 is given as monotherapy in continuous 28-day cycles.

ClinicalTrials.gov ID: NCT06593522

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic, non-squamous NSCLC harboring activating HER2 mutations in the tyrosine kinase domain, who are treatment-naïve for advanced disease. Patients will be randomized to receive either BAY 2927088, an oral reversible inhibitor targeting mutant HER2 and EGFR, or standard of care with pembrolizumab plus platinum-pemetrexed chemotherapy.

ClinicalTrials.gov ID: NCT06452277

Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, locally advanced or metastatic nonsquamous NSCLC harboring EGFR exon 20 insertion mutations (including those with stable, treated brain metastases), comparing standard first-line platinum-based chemotherapy plus zipalertinib—a selective, irreversible EGFR exon 20ins tyrosine kinase inhibitor—versus chemotherapy alone.

ClinicalTrials.gov ID: NCT05973773

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated metastatic NSCLC (non-squamous or squamous) and high PD-L1 expression (TPS ≥50%) without EGFR, ALK, or ROS1 alterations, comparing pembrolizumab monotherapy to pembrolizumab plus sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate linked to a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06170788

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic non-squamous NSCLC harboring HER2 kinase domain mutations, randomizing them to first-line treatment with either zongertinib, an oral selective inhibitor of HER2, or standard of care with pembrolizumab plus platinum-pemetrexed chemotherapy. Eligible patients must be previously untreated for advanced disease and have at least one measurable lesion.

ClinicalTrials.gov ID: NCT06151574

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with treatment-naive, stage IIIC or IV NSCLC (PD-L1 ≥1%, no EGFR/ALK/ROS1/RET alterations, ECOG 0-1), who will receive a combination of pembrolizumab and SX-682, an oral CXCR1/2 inhibitor designed to block myeloid-derived suppressor cell infiltration and enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT05570825